CEL-SCI Experiences 40% Surge on Multikine Study Analysis Outcome
CEL-SCI Experiences 40% Surge on Multikine Study Analysis Outcome
RapidEye After analyzing the Phase 3 data of the drug Multikine in the treatment of head and neck cancer, CEL-SCI’s stock on NYSE surged by 40% in morning trading on Friday. The company revealed that Multikine managed to reduce the five-year risk of death by 50% as per the results of the study. “The bias ...









